Financials Leo Acquisitions Corp Toronto S.E.
Equities
LEQ.H
CA5263612098
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 CAD | +33.33% | -.--% | -.--% |
Valuation
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Capitalization 1 | 17.87 | 2.874 |
Enterprise Value (EV) 1 | 14.06 | 3.009 |
P/E ratio | -1.54 x | -0.59 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | - | -6,93,581 x |
EV / FCF | -38,23,542 x | -21,25,619 x |
FCF Yield | -0% | -0% |
Price to Book | 6.57 x | -1.81 x |
Nbr of stocks (in thousands) | 1,12,961 | 1,11,338 |
Reference price 2 | 0.1582 | 0.0258 |
Announcement Date | 02/03/22 | 28/04/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net sales | - | - | - |
EBITDA | - | - | -4.338 |
EBIT 1 | -6.436 | -9.043 | -4.49 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -6.436 | -11.02 | -4.886 |
Net income 1 | -6.436 | -11.02 | -4.886 |
Net margin | - | - | - |
EPS | - | -0.1030 | -0.0437 |
Free Cash Flow | - | -3.678 | -1.415 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 17/02/21 | 02/03/22 | 28/04/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -4.755 | -2.95 | -2.596 | -1.884 | -1.813 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -4.756 | -2.914 | -3.014 | -2.006 | -1.868 |
Net income 1 | -4.933 | -2.733 | -3.014 | -2.006 | -1.868 |
Net margin | - | - | - | - | - |
EPS | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 30/08/21 | 29/11/21 | 02/03/22 | 30/05/22 | 29/08/22 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net Debt 1 | - | - | 0.13 |
Net Cash position 1 | 0.27 | 3.81 | - |
Leverage (Debt/EBITDA) | - | - | -0.031 x |
Free Cash Flow | - | -3.68 | -1.42 |
ROE (net income / shareholders' equity) | - | -1,113% | -867% |
ROA (Net income/ Total Assets) | - | -263% | -128% |
Assets 1 | - | 4.187 | 3.829 |
Book Value Per Share 2 | -0.0100 | 0.0200 | -0.0100 |
Cash Flow per Share 2 | 0.0100 | 0 | 0 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 17/02/21 | 02/03/22 | 28/04/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.52% | 11TCr | |
+11.38% | 11TCr | |
-12.64% | 2.22TCr | |
+0.44% | 2.13TCr | |
-4.18% | 1.9TCr | |
-37.85% | 1.85TCr | |
-8.58% | 1.68TCr | |
+37.41% | 1.25TCr | |
-23.95% | 808.97Cr |
- Stock Market
- Equities
- PSYB.H Stock
- LEQ.H Stock
- Financials Leo Acquisitions Corp